Notices and Reminders

Information for System for Award Management (SAM) Registration Expiration Notices

OUHSC’s System for Award Management (SAM) registration that is required for the submission of federal grants is expiring 10/28/21. Our central office management handles the renewal of SAM registration so there is no action required from any PI or department to renew this registration. We are aware it is expiring and it will be renewed prior to the deadline. However, we are unable to renew until shortly before the expiration date.

Because we cannot yet renew our registration, our submission systems are generating warnings like the one from NIH below. There is no action needed on your part and you do not need to contact ORA or GCA to have this registration renewed. SAM registration will be renewed prior to the deadline and will not impact any submissions prior to renewal.

Please share this information with your faculty and let me know if you have any questions or concerns.

iRIS will be down October 20-21 for a system upgrade to v13.01

The IRB electronic submission system, iRIS, will be unavailable on October 20-21 for an upgrade to Version 13.01. The new iRIS will have a new look and feel, add flexibility to the user’s dashboard, and eliminate bugs in previous versions. 

Please email the HRPP Office at 405-271-2045 or at irb@ouhsc.edu if you have any questions or would like to view a recording of the iRIS training for this upgrade.

ORA Reminders: Effective October 1^st, ORA requires applicants and recipients to use the updated Other Support format to submit with applications, Just-In-Time (JIT) and Research Performance Progress Reports (RPPRs). 

Because of the substantial changes and additional information that needs to be included, all Key Personnel on RPPRs are expected to provide Other Support in the updated format for each RPPR, regardless of when Other Support was last submitted for key personnel. Failure to follow the appropriate format on or after October 1^st, may delay processing your application/award by the ORA staff.

As a friendly reminder, please make sure you are carefully checking PeopleSoft and the budget justification to make sure OU Norman personnel are not included in the OUHSC personnel line.  Failure to properly list the OUHSC vs Norman personnel in the budget preparation phase may result in a rebudget request from the sponsor, and could negatively impact processing of the award.

Requirements for Acknowledging NIH-Supported Research

NIH funded researchers are required to accurately acknowledge NIH funding in publications, press releases, or other documents about research that is funded by NIH in whole or in part. To comply with NIH requirements, recipients must include the following (as described in Communicating and Acknowledging Federal Funding):

• A specific acknowledgment of NIH grant support
• An acknowledgement of the level of NIH funding, and
• A disclaimer as specified in Section 8.2.1 Rights in Data (Publication and Copyrighting) of the NIH Grants Policy Statement

Recipients should only acknowledge NIH awards on publications and other documents when the research activities that contributed to that publication directly arise from the award and are within the scope of the award being acknowledged. Please see the Communicating and Acknowledging Federal Funding and FAQs pages for more information on when, where, and how to acknowledge NIH funding. 

NSF Updates

NSF has released the updated Proposal & Award Policies & Procedures Guide (PAPPG) (NSF 22-1). This is effective for proposals submitted or due on or after October 4, 2021. Please see the list of PAPPG (NSF 22-1) significant changes and clarifications for all of the updates. Some of the key changes are listed below:

• Release of NSF Pre-award and Post-award Disclosures Relating to the Biographical Sketch and Current and Pending Support. This table identifies where pre- and post-award current and pending support disclosure information must be provided.
• Using the required NSF fillable pdf or generated SciENcv Biographical Sketch format, the page limit increased from two to three pages. 
• On Current and Pending Support, NSF now requires that information on objectives and overlap with other projects be provided.

Workshops and Seminars

Lunch and Learn - Introducing the Office of Innovation and Corporate Partnerships

Date: October 27, 2021, 12:00 pm

Description: Join us for an upcoming session of Innovation to Impact, a series of lunch discussions for faculty, staff and graduate students about the creation, management and commercialization of Intellectual Property (IP). This month’s speakers are:

John Hanak: Chief Innovation and Corporate Officer, Executive Director of Office of Innovation and Corporate Partnerships

Joyce Burch: Director of Corporate Partnerships and Regional Economic Development

Registration: https://oklahoma.zoom.us/meeting/register/tJwkce-oqjwpGtcydc1ajh-O9FdT3mRZsq_5

Save the Date - ORA Noon Conference offered via Zoom

Date: November 30, 2021 at 1:00 pm

Topic: Writing Successful Grants

Description: This talk goes beyond the basics of grant writing to discuss writing the specific aims and considerations for the research strategy, convey the NIH-recommended format and approach for each subsection, address and explain core-review criteria, and discuss scoring conventions, rigor, and reproducibility.

Registration: https://zoom.us/meeting/register/tJAkf-2sqj4oGtzrFXpVypgcCOiCEhqeSMIa

OUHSC Funding Opportunities

Presbyterian Health Foundation (PHF) Bridge Grant Program Cycle III Request For Applications

Deadline: November 10, 2021

Description: The primary objective of the PHF Bridge Grant Program is to provide funding to enhance OUHSC faculty competitiveness for extramural funding. OUHSC Principal Investigators are eligible if they meet the following criteria: 1) have submitted an extramural application within the past 18 months that was scored but not funded, 2) are requesting over $750,000 in total direct costs and over $200,000 in total facilities and administration (F&A) costs; and 3) received a review that ranks applications and provides critiques. This program can provide funding for up to $75,000 for one year. Guidelines and Application Form are attached for or can be found here.  If you have any questions, please email ORA4PHF@ouhsc.edu

Link to Full Announcement: https://research.ouhsc.edu/Resources/PHF-Funding-2021

Office of Technology Commercialization presents the following opportunities for researchers to engage with industry (click here for more information, or email otc@ou.edu or meredith-wilkerson@ouhsc.edu).  

• A global pharmaceutical company (requested anonymity) is seeking a range of collaboration opportunities for therapeutic targets and/or assets that target myeloid malignancies, specifically AML, MDS, MPN.  Specific pathways of interest include pro-apoptotic pathways, epigenetic targets, differentiation of myeloid malignant cells, tumor specific membrane targets, and splicing regulators.  Submission entails a 1-pg non-confidential summary of technology (deadline 10/21).
• Benitec Biopharma is seeking a range of collaboration opportunities with academia focused on monogenic targets that can be downregulated by expressed RNAi and replaced with RNAi insensitive transgene.  Submission entails a 1-pg non-confidential summary of technology (deadline 10/28).
• Johnson & Johnson Innovation is interested in connecting with academia to develop novel compounds, targets or pathways to repair kidney damage caused by CKD, DKD, AKI, ADPKD, or other types of kidney disease.  Out of scope: cell therapy approaches.  Submission entails a 1-pg non-confidential summary of technology (deadline 11/4).
• BioMarin Pharmaceutical Inc. is looking for early discovery academic research involving targets with genetic evidence in the area of kidney disease – with a focus on ADPKD and Alport Syndrome.  Submission entails a 1-pg non-confidential summary of technology (deadline 11/11).

New Clinical Study Opportunities (Please note this is NOT a solicitation for study subjects)

Several Pharmaceutical companies are looking for Principal Investigators to participate in the following clinical studies:

• Clinical Trial Opportunity in Sickle Cell Disease study - IQVIA Biotech LLC
• Valo Health Phase 2 Cardiovascular Trial For Post-Myocardial Infarction Patients
• Phase 2 Acute Myeloid Leukemia (AML) Clinical Trial

Please contact Scott Davis at scott-davis@ouhsc.edu if you would like to receive more information on any of these studies. The resulting confidentiality and/or clinical study agreement will need to be routed to the Office of Research Administration.

NIH Notices 

• Notice of Pre-Application Webinar for RFA-DK-21-026, Silvio O. Conte Digestive Diseases Research Core Centers (P30 Clinical Trial Optional)
  (NOT-DK-21-031)
• Notice of Information: Upcoming Prize Competition Announcement for the NIH Technology Accelerator Challenge - Maternal Health
  (NOT-EB-21-028)
• Notice of Correction to Instructions for the Submission of Multi-Component Applications in RFA-CA-21-040, "Radiation Oncology-Biology Integration Network (ROBIN) Centers (U54 Clinical Trial Required)"
  (NOT-CA-21-123)
• Notice of Correction to the Key Dates in PAS-21-270, AIDS-Science Track Award for Research Transition (R03 Clinical Trial Optional)"
  (NOT-DA-21-090)
• Notice of Change in Effort Requirements for RFA-DK-21-024, Pediatric Centers of Excellence in Nephrology (P50 Clinical Trial Optional)
  (NOT-DK-22-001)

• Notice of Change to Key Dates for RFA-TR-20-001, Ethical Issues in Translational Science (R01 Clinical Trial Optional)
  (NOT-TR-22-001)
• Notice of Intent to Publish a Funding Opportunity Announcement for Scalable and Systematic Neurobiology of Psychiatric and Neurodevelopmental Disorder Risk Genes: Data Resource and Administrative Coordination Center (U24 Clinical Trial Not Allowed)
  (NOT-MH-22-015)
• Notice of Intent to Publish a Funding Opportunity Announcement for Scalable and Systematic Neurobiology of Psychiatric and Neurodevelopmental Disorder Risk Genes: Assay and Data Generation Centers (RM1 Clinical Trial Not Allowed)
  (NOT-MH-22-016)
• Notice of Special Interest (NOSI): Dietary, Physical Activity, Sedentary Behavior and Sleep Assessment Methodologies Among Infants and Young Children (Birth to 5 years) through Adults
  (NOT-CA-21-108)
• Notice of Special Interest (NOSI): Dietary Effects on Nutrient Sensing Pathways in Tumor Etiology and Prevention
  (NOT-CA-21-121)
• Notice of Special Interest (NOSI): Biologic Factors Underlying Dental, Oral, and Craniofacial Health Disparities
  (NOT-DE-21-013)

NOTE: When only one application is allowed per Institution according to the sponsor instructions, a one-page letter of intent summarizing the proposed project should be submitted to the Vice President for Research at least two months prior to the application deadline (unless  otherwise noted).  The letters of intent will be reviewed and a single application will be chosen for submission from the University.

NIH Funding Opportunities

• Genomic Curriculum Development for Medical Students (R25 Clinical Trial Not Allowed)
  (PAR-21-312)
  Application Receipt Date(s): January 25, 2024
• Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01 Basic Experimental Studies with Humans Required)
  (PAR-21-349)
  Application Receipt Date(s): June 21, 2024
• Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01 Clinical Trials Not Allowed)
  (PAR-21-350)
  Application Receipt Date(s): June 21, 2024
• Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01 Clinical Trial Required)
  (PAR-21-352)
  Application Receipt Date(s): September 07, 2024
• NIDCD Clinical Research Center Grant (P50 Clinical Trial Optional)
  (PAR-22-025)
  Application Receipt Date(s): October 09, 2024
• Pediatric Obesity Discovery Science Research to Improve Understanding of Risk and Causal Mechanisms for Obesity in Early Life (R01 Clinical Trial Optional)
  (RFA-DK-21-025)
  Application Receipt Date(s): March 08, 2022
• Virtual Consortium for Translational/Transdisciplinary Environmental Research (ViCTER) (R01 Clinical Trial Optional)
  (RFA-ES-21-007)
  Application Receipt Date(s): February 01, 2024
• IDeA Regional Entrepreneurship Development (I-RED) Program (STTR) (UT2 Clinical Trial Not Allowed)
  (RFA-GM-22-001)
  Application Receipt Date(s): January 05, 2022
• Pilot Practice-based Research for Primary Care Suicide Prevention (R34 Clinical Trial Optional)
  (RFA-MH-22-120)
  Application Receipt Date(s): June 21, 2022
• Neurosurgeon Research Career Development Program (NRCDP) (K12 Independent Clinical Trial Not Allowed)
  (RFA-NS-21-019)
  Application Receipt Date(s): December 15, 2021
• HEAL Initiative: Advancing Health Equity in Pain Management (R61/R33 Clinical Trial Required)
  (RFA-NS-22-002)
  Application Receipt Date(s): December 09, 2021
• SPARC Human Open Research Neural Engineering Technologies (HORNET) Initiative (U41 Clinical Trial Not Allowed)
  (RFA-RM-21-024)
  Office of Strategic Coordination (Common Fund)
  Application Receipt Date(s): January 12, 2022

Other Funding Opportunities

Description: MBArC deploys up to $1million/year in training, proof-of-concept milestone/deliverable-driven funding and support to accelerate the translation of your technology into a commercial product. The Program is designed to bridge the gap between academic research and industry by providing resources to researchers from 16 institutions in the Midwest to perform experiments and generate data that can attract follow-on funding from federal sources, investors and strategic partners to continue commercialization of the technology. All technologies (i.e., Therapeutic, Diagnostic, Device, Tool and Software) with the potential to directly impact human health are considered for funding. Technologies that are already licensed or optioned to a company are not eligible. Select applicants are required to attend a Commercialization Boot Camp that is offered annually by the Program. MBArC supports each project with a maximum of $100,000, and the applicant is required to show at least an equal (1:1) cash match commitment from non-federal sources (e.g., recipient institutions, foundations, for-profit investors, other state resources) to be eligible for funding.

Proposals Due: The 2022 Call for Letters of Intent is scheduled to go out in late October, 2021.

Link to Full Announcement:  https://medicine.missouri.edu/offices-programs/midwest-biomedical-accelerator-consortium/mbarc-application-requirements

If you would like to learn more about the Program and/or would like to be notified about our 2022 Call for Letters of Intent, please contact the MBArC Program Office:
Jaya Ghosh, PhD (Lead Program Manager) | ghoshj@missouri.edu
Kristin Hatton (Assistant Program Manager) | hattonk@missouri.edu

Chan Zuckerberg Initiative (CZI) Single-Cell Biology Data Insights RFA

Description: Given the growth of the single-cell biology field and the rapid increase in available data, the Chan Zuckerberg Initiative (CZI)’s newest funding opportunity seeks to support computational experts to advance tools and resources that make it possible to gain greater insights into health and disease from existing single-cell biology datasets. The CZI Single-Cell Biology Data Insights Request for Applications (RFA) invites applications for projects that will advance the fields of single-cell biology and data science. Projects should address computational challenges and bottlenecks associated with boosting the utility and insight from available single-cell biology datasets. Projects may include dedicated efforts to improve existing computational tools and standards, benchmarking classes of tools, integration of available datasets to enable greater biological insight, development of new features that support interoperability of current data or tools, and other major challenges brought forward.

Proposals Due: December 14, 2021

Link to Full Announcement: https://chanzuckerberg.com/rfa/single-cell-data-insights/

Cystic Fibrosis Foundation 

The Fall 2021 RFAs for Research Grants, Pilot & Feasibility, Post-Doctoral Research Fellowships and Postdoc-to-Faculty Transition Awards for both the Research and Research Training and Path to a Cure - Academic Programs will be published in October, with a deadline of December 9, 2021!

Additional Open Funding Opportunities can be found here.

The Mselanoma Research Alliance (MRA) 2021-2022 Request for Proposal

Team Science Award Letters of Intent Due: October 6, 2021

Young Investigator Award Eligibility Checklist Due: November 3, 021

Young Investigator and Pilot Awards Full Proposals Due: November 17, 2021

Team Science Award Full Proposals Due (from invited applicants) Due: January 19, 2022

Description: MRA anticipates supporting at least $12.8 million in new funding. Proposals will be accepted for Team Science, Academic-Industry Partnership, Young Investigator, and Pilot Awards. Special Opportunities are also available in immunotherapy, women in research, and patient-centric clinical trials. MRA encourages applications from a diverse pool of investigators. Full descriptions of each award opportunity offered, including all Special Opportunity Awards, as well as eligibility criteria and instructions can be found on the MRA website at CureMelanoma.org/RFP 

Proposals should be submitted via the proposalCENTRAL online application tool: https://proposalcentral.com/

https://www.curemelanoma.org/research/request-for-proposals/

OKLAHOMA NSF EPSCoR Summer 2022 Research Experience for Undergraduate Students (REU)

Description: OKLAHOMA NSF EPSCoR REU awards provide opportunities for undergraduate students from regional universities and colleges across the state to perform research in collaboration with Oklahoma’s comprehensive research campuses (OU, OSU, TU, NRI) during the summer months. The goal of the program is to enhance pursuit of graduate degrees by students at regional undergraduate institutions and strengthen network collaborations across all higher education institutions in Oklahoma. Students benefit from hands-on research experiences in STEM fields and one-on-one guidance from faculty mentors. Proposals will be awarded via a competitive review process based on proposal integrity and the engagement of a diversity of students from regional institutions.

Proposals Due: November 17, 2021 

Link to Full Announcement: http://www.okepscor.org/2022-research-experience-undergraduates  

Oklahoma Center for Adult Stem Cell Research (OCASCR)

Microbiome Interactions with the Nervous System in Health and Disease
Email Kelly-gentry@ocascr.org for more information.

Grant Deadline: January 2022

http://www.ocascr.org/